Stada Arz opts to proceed with joint takeover from Bain Capital and Cinven

10 April 2017

Shares of German generic drugmaker Stada Arzneimittel (SAZ: Xetra) leapt 11.5% to 64.72 euros this morning, after the company revealed it has made a decision on which of several takeover proposals it favored.

With a total value of 66.00 euros per Stada share, consisting of the offer price of 65.28 euros plus an expected dividend of 0.72 euros to be paid by Stada during the offer period, private equity firms Bain Capital and Cinven have presented the most financially appealing offer.

As well as Cinven and Bain Capital, Advent, CVC and Permira reportedly were also looking at buying Stada.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK